Drugs / MK-8237
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01852825 | Nov 2013 → Jul 2015 | allergic rhinitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01678807 | Oct 2012 → May 2013 | perennial allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01644617 | Oct 2012 → Aug 2013 | perennial allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01700192 | Jan 2013 → Apr 2015 | perennial allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01700192 ↗ |
| Route | Other | “administered sublingually” NCT01644617 ↗ |